accepting new patients

Dr. Phil Scheinberg is Chief of Clinical Hematology at the Hospital Sao Jose, Beneficencia Portuguesa de Sao Paolo in Brazil. He received his medical degree in 1995 at the University of Santo Amaro in Sao Paulo, Brazil and completed his residency (1997-2001) at Mount Sinai Medical Center in Miami Beach, FL where he became Medical Chief Resident. Dr. Scheinberg held a Hematology/Oncology Fellowship (2001-2005) before becoming a staff clinician at the Hematology Branch of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH) in Bethesda, MD. During his

Earlier this summer, AAMDSIF called for research proposals addressing Paroxysmal Nocturnal Hemoglobinuria (PNH). Robert A. Brodsky, MD, is the Johns Hopkins Family Professor of Medicine and Oncology and Director of the Division of Adult Hematology. He has a long track record of funded research through the NIH and through foundation grants, and serves as the Director of the Johns Hopkins Hematology Fellowship program, as well as the PI for the Johns Hopkins T32 in hematology and co-PI of a K12 in benign hematology. His focus on PNH and interest in translational medicine led his laboratory to

Dr. Kirk Schultz is a Professor at the University of British Columbia, BC Children’s Hospital, and the Child and Family research Institute (CFRI) who has published over 130 peer-reviewed articles in scientific journals. He is a Pediatric Hematologist/Oncologist focused on new therapies and rejection in Blood and Marrow Transplantation (BMT) and immune therapy of blood cancers.Dr. Schultz was the recipient of the CIHR/Wyeth Clinical Research Chair in Transplantation and is past chair of the Pediatric BMT Consortium the largest children’s BMT clinical trials group in the world. He was recently

Daria Babushok’s research is focused on understanding the genetic changes that can arise in the bone marrow of patients with aplastic anemia, and on how they affect the patients’ prognosis and treatment outcomes. Dr. Babushok has completed a clinical hematology-oncology fellowship at the Hospital of the University of Pennsylvania, and is currently a junior physician-scientist investigator at the University of Pennsylvania under the mentorship of Dr. Monica Bessler. In a study recently published in the journal of Cancer Genetics and conducted with the support of the AA&MDS International

Dr. Gondek is a current Evans Fellow at Johns Hopkins University in the Department of Oncology, working with Dr. Amy Dezern on research related to signaling pathways in MDS stem cells. Dr. Gondek explained that the mechanism of progression in MDS is poorly understood, and he hopes through his work to clarify some of the factors that contribute to progression. He is the Principal Investigator on one pilot project currently underway within the MDS Clinical Research Consortium, working with a particular signaling pathway named the Hedgehog pathway. Dr. Gondek describes the Hedgehog (Hh) pathway

David Margolis, MD, received his medical degree from the University of Wisconsin-Madison in 1989. He is currently a professor of pediatrics at the Medical College of Wisconsin, located in Milwaukee, and is program director of Children’s Hospital of Wisconsin’s Blood and Bone Marrow Transplant Program. His clinical and research interests include taking care of children and young adults with aplastic anemia as well as alternative donor blood and bone marrow transplants for children and young adults with aplastic anemia, sickle cell anemia and leukemia.

My main academic and clinical objective is to, if not cure, at least contribute to significantly better outcomes for patients with Myelodysplastic Syndromes (MDS). I am the Chief of the Section of MDS in the Department of Leukemia at MD Anderson Cancer Center. I have built this into the largest clinical program of its class. One hundred percent of my research and clinical effort is devoted to patients with MDS.

Dr. Cogle is an associate professor of medicine at the University of Florida, Gainesville. He has clinical and research expertise in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and allogeneic hematopoietic cell transplant. Dr. Cogle leads a research laboratory that studies the biology of MDS and AML, and his group has successfully translated his discoveries into new treatments for patients. Dr. Cogle’s goal is to fi nd cures for MDS and leukemia, educate patients and providers about the distinct heterogeneity of these diseases, educate policy makers that blood cancers are a

Dr. Odenike is Professor of Medicine and Director of the Leukemia Program at the University of Chicago. Her clinical interests are in acute and chronic leukemias, myeloproliferative neoplasms, myelodysplastic syndromes, and stem cell transplantation. Her research is focused on the development of novel therapeutic agents for the treatment of acute and chronic leukemias, and chronic myeloproliferative diseases, with the ultimate goal of improving treatment options for patients with these diseases. She is the principal investigator on a number of clinical trials investigating molecularly targeted